Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
Xin Yan YangJohn Carson AllenEdwin Jonathan AslimKae Jack TayShyi Peng John YuenRavindran KanesvaranMelvin Lee Kiang ChuaTsung Wen ChongSun Sien Henry HoLui-Shiong LeePublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
During 12 weeks of neoadjuvant apalutamide in organ-confined prostate cancer, the overall patient-reported HRQoL outcomes were maintained, but fatigue and sexual dysfunction were observed in those patients.
Keyphrases
- prostate cancer
- radical prostatectomy
- patient reported outcomes
- phase ii
- patient reported
- clinical trial
- rectal cancer
- end stage renal disease
- open label
- lymph node
- phase iii
- locally advanced
- chronic kidney disease
- ejection fraction
- newly diagnosed
- oxidative stress
- squamous cell carcinoma
- prognostic factors
- type diabetes
- peritoneal dialysis
- radiation therapy
- randomized controlled trial
- sleep quality
- gestational age
- adipose tissue
- weight loss
- depressive symptoms